Document Detail


Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome.
MedLine Citation:
PMID:  12670887     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Using a tissue microarray cohort of 300 breast cancers and 84 samples of normal breast epithelium, we analyzed HER2/neu expression and compared traditional clinical (manual) scoring with a recently developed system for the quantitative measurement of immunohistochemical stains (AQUA). As expected, both methods identified a population (10-15%) of high-HER2-expressing tumors with poor 30-year disease-related survival. Using AQUA analysis, we found that normal epithelium expresses a low but detectable level of HER2 and that 17.5% of tumors exhibit similar low-level HER2 expression. This low group was not definable by manual scoring. Surprisingly, HER2-normal tumors were as aggressive as HER2-overexpressing tumors. Our studies suggest that in situ quantitative measurement of HER2 stratifies breast tumors into three expression levels: normal, intermediate, and high, where both normal and high levels are associated with a worse outcome.
Authors:
Robert L Camp; Marisa Dolled-Filhart; Bonnie L King; David L Rimm
Related Documents :
25023327 - Systemic administration of platelets incorporating inactivated sendai virus eradicates ...
6094037 - Tissue proteins in breast cancer, as studied by use of two-dimensional electrophoresis.
23301497 - Size-dependent tumor penetration and in vivo efficacy of monodisperse drug-silica nanoc...
1252327 - Oestradiol synthesis from c19 steroids by human breast cancers.
23397427 - Analysis of metallothionein and vimentin immunoreactivity in pharyngeal squamous cell c...
17036057 - Dendritic cells transfected with interleukin-12 and tumor-associated antigen messenger ...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Cancer research     Volume:  63     ISSN:  0008-5472     ISO Abbreviation:  Cancer Res.     Publication Date:  2003 Apr 
Date Detail:
Created Date:  2003-04-02     Completed Date:  2003-04-22     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  2984705R     Medline TA:  Cancer Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1445-8     Citation Subset:  IM    
Affiliation:
Department of Pathology, Yale University, School of Medicine, New Haven, Connecticut 06520, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Breast / metabolism
Breast Neoplasms / metabolism*,  pathology
Cohort Studies
Epithelium / metabolism
Humans
Immunohistochemistry
Lymphatic Metastasis
Multivariate Analysis
Prognosis
Receptor, erbB-2 / biosynthesis*
Grant Support
ID/Acronym/Agency:
K0-8 ES11571/ES/NIEHS NIH HHS; R0-1 GM57604/GM/NIGMS NIH HHS
Chemical
Reg. No./Substance:
EC 2.7.10.1/Receptor, erbB-2

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ.
Next Document:  Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method...